Basel, Switzerland, October 15, 2007 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today that Swissmedic has accepted for review, the marketing authorization application for alitretinoin. This application supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema.
